High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials

PURPOSE: Adjuvant high-dose chemotherapy (HDC) with autologous hematopoietic stem-cell transplantation (AHST) for high-risk primary breast cancer has not been shown to prolong survival. Individual trials have had limited power to show overall benefit or benefits within subsets. METHODS: We assembled...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Berry, Donald A., Ueno, Naoto T., Johnson, Marcella M., Lei, Xiudong, Caputo, Jean, Rodenhuis, Sjoerd, Peters, William P., Leonard, Robert C., Barlow, William E., Tallman, Martin S., Bergh, Jonas, Nitz, Ulrike A., Gianni, Alessandro M., Basser, Russell L., Zander, Axel R., Coombes, R. Charles, Roché, Henri, Tokuda, Yutaka, de Vries, Elisabeth G.E., Hortobagyi, Gabriel N., Crown, John P., Pedrazzoli, Paolo, Bregni, Marco, Demirer, Taner
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2011
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4322115/
https://ncbi.nlm.nih.gov/pubmed/21768471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.32.5910
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars